Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Voyager Therapeutics Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 2/6
Voyager Therapeutics has been growing earnings at an average annual rate of 36.2%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been growing at an average rate of 10.5% per year. Voyager Therapeutics's return on equity is 2.7%, and it has net margins of 6.3%.
Anahtar bilgiler
36.2%
Kazanç büyüme oranı
35.9%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 17.0% |
| Gelir büyüme oranı | 10.5% |
| Özkaynak getirisi | 2.7% |
| Net Marj | 6.3% |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround
Aug 26Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 09
Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S
Aug 08Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis
Jun 05There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise
Mar 15Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier
Mar 08What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates
Mar 04Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement
Jan 04Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target
Oct 04Voyager Therapeutics hires new finance chief
Sep 07Voyager Therapeutics GAAP EPS of -$0.50 misses by $0.02
Aug 04Looking Back In On Voyager Therapeutics
Jun 08Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates
May 12Voyager Does A Reboot After First Generation Failures
Mar 25Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky
Feb 07Voyager Therapeutics: Another Year, Another Deal
Nov 21Gelir ve Gider Dağılımı
Voyager Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 144 | 9 | 37 | 0 |
| 31 Mar 24 | 119 | -3 | 35 | 0 |
| 31 Dec 23 | 250 | 132 | 36 | 0 |
| 30 Sep 23 | 158 | 52 | 34 | 0 |
| 30 Jun 23 | 195 | 96 | 33 | 0 |
| 31 Mar 23 | 191 | 99 | 32 | 0 |
| 31 Dec 22 | 41 | -46 | 31 | 0 |
| 30 Sep 22 | 71 | -17 | 31 | 0 |
| 30 Jun 22 | 31 | -60 | 32 | 0 |
| 31 Mar 22 | 32 | -71 | 35 | 0 |
| 31 Dec 21 | 37 | -71 | 37 | 0 |
| 30 Sep 21 | 16 | -93 | 37 | 0 |
| 30 Jun 21 | 132 | 18 | 37 | 0 |
| 31 Mar 21 | 160 | 39 | 35 | 0 |
| 31 Dec 20 | 171 | 37 | 35 | 0 |
| 30 Sep 20 | 197 | 40 | 37 | 0 |
| 30 Jun 20 | 100 | -61 | 37 | 0 |
| 31 Mar 20 | 117 | -41 | 37 | 0 |
| 31 Dec 19 | 104 | -44 | 36 | 0 |
| 30 Sep 19 | 74 | -54 | 40 | 0 |
| 30 Jun 19 | 55 | -59 | 38 | 0 |
| 31 Mar 19 | 12 | -96 | 36 | 0 |
| 31 Dec 18 | 8 | -88 | 34 | 0 |
| 30 Sep 18 | 12 | -78 | 26 | 0 |
| 30 Jun 18 | 11 | -81 | 24 | 0 |
| 31 Mar 18 | 10 | -74 | 22 | 0 |
| 31 Dec 17 | 10 | -71 | 20 | 0 |
| 30 Sep 17 | 6 | -74 | 18 | 0 |
| 30 Jun 17 | 8 | -59 | 16 | 0 |
| 31 Mar 17 | 11 | -50 | 15 | 0 |
| 31 Dec 16 | 14 | -40 | 13 | 0 |
| 30 Sep 16 | 17 | -34 | 13 | 0 |
| 30 Jun 16 | 18 | -32 | 12 | 0 |
| 31 Mar 16 | 20 | -30 | 12 | 0 |
| 31 Dec 15 | 17 | -38 | 10 | 0 |
| 30 Sep 15 | 12 | -35 | 8 | 0 |
| 30 Jun 15 | 7 | -32 | 7 | 0 |
| 31 Mar 15 | 3 | -30 | 6 | 0 |
| 31 Dec 14 | 0 | -18 | 5 | 0 |
Kaliteli Kazançlar: VYGR has high quality earnings.
Büyüyen Kar Marjı: VYGR's current net profit margins (6.3%) are lower than last year (49.2%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: VYGR has become profitable over the past 5 years, growing earnings by 36.2% per year.
Büyüme Hızlandırma: VYGR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Kazançlar vs. Sektör: VYGR had negative earnings growth (-90.6%) over the past year, making it difficult to compare to the Biotechs industry average (0.5%).
Özkaynak Getirisi
Yüksek ROE: VYGR's Return on Equity (2.7%) is considered low.